About us


    INHIBITEC anticuerpos is a pre clinical and clinical stage biotechnology company founded in 2019 in Santander, (Cantabria), Spain, focused on the development of a therapeutic monoclonal antibody (mAB) to be used in cure of autoinmune diseases but mainly in Psoriasis and Psoriasis Arthritis.

    INHIBITEC has an exclusive license of a technology developed by the National Scientific and Research Council (CSIC), at the Institute of Biotechnlogy and Biomedicine in Cantabria (IBBTEC) and the Universidad de Cantabria in Santander.

    INHIBITEC is a private held funded company that combines a strong science background and a highly skilled team in the biotech and human health industries.

    Our commitment is to bring our solutions to improve the quality of life of the people creating a better environment for them.